The deal size was increased to $200M in common stock from $150M in common stock and the range was $18.50-$19.00. Goldman Sachs, JPMorgan, TD Securities and Stifel acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNDX:
- 3 Best Stocks to Buy Now, 12/14/2023, According to Top Analysts
- Syndax says AUGMENT-101 trial of revumenib met primary endpoint
- Syndax announces data from multiple trials on revumenib
- Incyte, Syndax announce full results from pivotal Phase 2 AGAVE-201 trial
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
